1454666-76-2

Upstream product

• 215184-78-4 5-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 1035235-26-7 tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 481075-58-5 2-bromo-1-iodo-4-(trifluoromethyl)benzene 
• 1454667-10-7 tert-butyl 5-(2-bromo-4-(trifluoromethyl)phenyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1454667-12-9 5-(2-bromo-4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 163133-86-6 pyrimidin-4-amine 
• 1454667-86-7 5-(2-bromo-4-(trifluoromethyl)phenyl)-3,4-dihydroisoquinoline-2(1H)-sulfonyl chloride 

Relevant academic research and scientific papers

SULFAMIDE SODIUM CHANNEL INHIBITORS

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.